Brightsurf Science News & Current Events

July 06, 2019
Data demonstrate efficacy of more flexible dose of regorafenib to relieve side-effects in mCRC patients
some of the adverse events related to the use of regorafenib often limits its use in clinical practice.

Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations
The 3-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Targeted therapy combination improves survival in patients with advanced bowel cancer
New data have shown for the first time that a combination of targeted therapies can improve survival in patients with advanced bowel cancer.

Plant nutrient detector breakthrough
Findings from La Trobe University-led research could lead to less fertilizer wastage, saving millions of dollars for Australian farmers. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to